O‘TKIR MIELOBLAST LEYKOZNING GENETIK TASHXISLASH MEZONLARINI TAKOMILLASHTIRISH

Authors

  • Asmo Moxammad Din tibbiyot fanlari bo‘yicha falsafa doktori (PhD), Molekulyar genetika, sitogenetika va FISH laboratoriyasi mudiri, Respublika ixtisoslashtirilgan gematologiya ilmiy amaliy tibbiyot markazi

Keywords:

O‘tkir mieloblast leykoz (O‘ML), Molekulyar genetika, Sitogenetika, FISH, Biochip, Translokatsiya, Prognoz.

Abstract

Dolzarbligi: O‘tkir mieloblast leykoz (O‘ML) geterogenligi va agressiv kechishi bilan ajralib turadi. O‘zbekistonda O‘ML diagnostikasini jahon standartlariga moslashtirish, shuningdek, mahalliy aholi populyatsiyasiga xos bo‘lgan genetik markerlarni aniqlash dolzarb muammo hisoblanadi.

Maqsad: Gemopoezning o‘tmishdosh hujayralaridagi yuqori maxsus molekulyar-genetik va sitogenetik o‘zgarishlarni o‘rganish.

Usullar: RIGIATMda birlamchi tashxislangan 70 nafar O‘ML va 30 nafar O‘LL (nazorat) bemorlarining suyak ko‘migi va periferik qoni namunalari tahlil qilindi. Zamonaviy LK-Biochip texnologiyasi (multipleks PZR va gibridizatsiya) hamda standart sitogenetik usullardan foydalanildi. Tadqiqot dizayni "holat-nazorat" (case-control) usulida olib borildi.

Natijalar: 49% O‘ML bemorlarida mutatsion o‘zgargan kariotip aniqlandi. Biochip tahlili natijasida 32.9% O‘ML bemorlarida turli mutatsiyalar topildi. Tadqiqotda aniqlangan O‘zbekiston aholisida O‘ML bemorlarida genetik o‘zgarishlarning umumiy spektral miqdori quyidagilarni tashkil etdi (t(8;21), t(15;17), inv(16), +8, -7). 

Xulosa: Olingan ma’lumotlarning tahlili O‘ML kasalligining kechish shakli va klinik namoyon bo‘lishi hamda saraton hujayralaridagi asosiy genetik o‘zgarishlar o‘rtasidagi aloqani aniqlashga imkon beradi.

References

Wachter F, Pikman Y. Pathophysiology of Acute Myeloid Leukemia. Acta Haematol. 2024;147(2):229-246. doi: 10.1159/000536152.

Weinberg OK, Porwit A, Orazi A, et al. The International Consensus Classification of acute myeloid leukemia. Virchows Arch. 2023;482(1):27-37. doi: 10.1007/s00428-022-03430-4.

O‘zbekiston Respublikasi Prezidentining Farmoni. “2022–2026-yillarga mo‘ljallangan Yangi O‘zbekistonning taraqqiyot strategiyasi to‘g‘risida”, 28.01.2022 yildagi PF-60-son. URL: https://lex.uz/docs/5841063

Edmund J, Thaliath LJ, Meleveedu K. Acute myeloid leukemia in the medically unfit elderly patients. Leuk Res. 2023;130:107306. doi: 10.1016/j.leukres.2023.107306.

Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108(2):308-320. doi: 10.3324/haematol.2022.280801.

Alhajahjeh A, Bewersdorf JP, Bystrom RP, et al. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leuk Lymphoma. 2024;65(11):1541-1551. doi: 10.1080/10428194.2024.2367040.

Garcia-Rodriguez MJ, Flores Y, Salinas J, et al. Acute myeloid leukemia: a comprehensive update. Curr Opin Hematol. 2025;32(6):308-313. doi: 10.1097/MOH.0000000000000897.

Shi X, Feng M, Nakada D. Metabolic dependencies of acute myeloid leukemia stem cells. Int J Hematol. 2024;120(4):427-438. doi: 10.1007/s12185-024-03789-x.

Woods JD, Klepin HD. Geriatric Assessment in Acute Myeloid Leukemia. Acta Haematol. 2024;147(2):219-228. doi: 10.1159/000535500.

Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025;100(5):860-891. doi: 10.1002/ajh.27625.

Chen EC, Shimony S, Luskin MR, Stone RM. Biology and Management of Acute Myeloid Leukemia With Mutated NPM1. Am J Hematol. 2025;100(4):652-665.

doi: 10.1002/ajh.27600.

Published

2026-01-30 — Updated on 2026-02-12

Versions

Issue

Section

Articles